Back to Journals » Clinical Ophthalmology » Volume 8

An emerging treatment option for glaucoma: Rho kinase inhibitors

Authors Wang S, Chang R

Received 19 February 2014

Accepted for publication 31 March 2014

Published 9 May 2014 Volume 2014:8 Pages 883—890


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Sean K Wang,1 Robert T Chang2

1Stanford University, Stanford, CA, USA; 2Stanford University School of Medicine, Stanford, CA, USA

Abstract: Rho kinase (ROCK) inhibitors are a novel potential class of glaucoma therapeutics with multiple compounds currently in phase II and III US Food and Drug Administration trials in the United States. These selective agents work by relaxing the trabecular meshwork through inhibition of the actin cytoskeleton contractile tone of smooth muscle. This results in increased aqueous outflow directly through the trabecular meshwork, achieving lower intraocular pressures in a range similar to prostaglandins. There are also animal studies indicating that ROCK inhibitors may improve blood flow to the optic nerve, increase ganglion cell survival, and reduce bleb scarring in glaucoma surgery. Given the multiple beneficial effects for glaucoma patients, ROCK inhibitors are certainly a highly anticipated emerging treatment option for glaucoma.

Keywords: ROCK inhibitors, actin cytoskeleton, aqueous dynamics review

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]